Skip to main content
SpringerLink
Log in

Clinical trials in metastatic hormone-refractory prostate cancer: Improving docetaxel therapy by targeting bone-related growth factors

  • Clinical Trials Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moore CN, Creel P, Petros W, et al.: Phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC) [abstract]. J Clin Oncol Proc ASCO 2006, 24(18S):14504.

    Google Scholar 

  2. Petrylak DP, Tangen CM, Hussain MH, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513–1520.

    Article  PubMed  CAS  Google Scholar 

  3. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502–1512.

    Article  PubMed  CAS  Google Scholar 

  4. Carducci MA, Nelson JB, Bowling MK, et al.: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002, 20:2171–2180.

    Article  PubMed  CAS  Google Scholar 

  5. Nelson JB: Endothelin receptor antagonists. World J Urol 2005, 23:19–27.

    Article  PubMed  CAS  Google Scholar 

  6. Carducci MA, Jimeno A: Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006, 12(20 Pt 2):6296s–6300s.

    Article  PubMed  CAS  Google Scholar 

  7. Akhavan A, McHugh KH, Guruli G, et al.: Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006, 8:725–732.

    Article  PubMed  CAS  Google Scholar 

  8. Petrylak D, Mohile SG, Shelton G, et al.: Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC) [abstract]. J Clin Oncol Proc ASCO 2006, 24(18S):4512.

    Google Scholar 

Download references

Authors
  1. Daniel P. Petrylak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petrylak, D.P. Clinical trials in metastatic hormone-refractory prostate cancer: Improving docetaxel therapy by targeting bone-related growth factors. Curr Oncol Rep 9, 211–212 (2007). https://doi.org/10.1007/s11912-007-0023-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0023-2

Keywords

Search

Navigation